ALK(002940)2024-04-26 09:11Financial Performance - The company's revenue for Q1 2024 was ¥407,993,014.11, a decrease of 3.89% compared to ¥424,507,176.32 in the same period last year[4] - Net profit attributable to shareholders was ¥28,218,693.81, down 40.05% from ¥47,070,207.68 year-on-year[4] - Total operating revenue for Q1 2024 was CNY 407,993,014.11, a decrease of 3.6% from CNY 424,507,176.32 in the previous period[20] - Net profit for Q1 2024 was CNY 47,410,347.34, a decrease of 8.2% compared to CNY 51,527,134.08 in the previous period[20] - The net profit attributable to the parent company for Q1 2024 is CNY 28,218,693.81, a decrease of 40.0% compared to CNY 47,070,207.68 in Q1 2023[21] - The total comprehensive income for Q1 2024 is CNY 47,410,347.34, compared to CNY 51,527,134.08 in Q1 2023, reflecting a decrease of 7.0%[21] Cash Flow and Liquidity - The net cash flow from operating activities increased by 90.03% to ¥161,258,174.92, compared to ¥84,860,705.56 in Q1 2023[9] - Cash and cash equivalents at the end of Q1 2024 amount to CNY 971,924,461.13, up from CNY 663,576,967.12 at the end of Q1 2023, indicating a growth of 46.3%[23] - The total cash inflow from financing activities in Q1 2024 is CNY 118,414,427.89, significantly higher than CNY 35,250,000.00 in Q1 2023[23] - The cash outflow for investing activities in Q1 2024 is CNY 65,792,371.60, down from CNY 86,224,813.66 in Q1 2023, showing a reduction of 23.6%[23] - The company received CNY 12,243,026.76 in tax refunds during Q1 2024, compared to CNY 42,800.81 in the previous year, marking a substantial increase[22] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥3,133,172,014.65, reflecting a 3.75% increase from ¥3,019,990,734.37 at the end of the previous year[4] - Total liabilities increased to CNY 1,264,983,376.27, up 6.5% from CNY 1,187,721,064.95 at the beginning of the period[20] - Inventory at the end of the period was CNY 408,474,783.41, an increase of 3.0% from CNY 393,443,248.92 at the beginning of the period[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,331[11] - The largest shareholder, Shenzhou JunTai Investment Co., Ltd., holds 35.44% of shares, totaling 71,485,000 shares, with 16,217,500 shares pledged[11] - The top ten shareholders hold a total of 61.77% of the shares, indicating a concentrated ownership structure[11] - The company has not reported any changes in the participation of the top ten shareholders in margin trading[13] Research and Development - R&D expenses surged by 136.44% to ¥49,086,015.25, up from ¥20,760,455.04 in the previous year[8] - Research and development expenses increased significantly to CNY 49,086,015.25, up 136.5% from CNY 20,760,455.04 in the previous period[20] Strategic Developments - The company has entered into a strategic cooperation agreement with Shanghai Qinhuali Biopharmaceutical Technology Co., Ltd. for the development of a drug based on the QHL-1618 molecule[13] - The company completed a share swap with Hunan Changxing Biopharmaceutical Co., Ltd., valuing the total equity of Hunan Jianrui Pharmaceutical Technology Co., Ltd. at 26.08695 million RMB[14] - The company holds a 19% stake in the newly established Hangzhou Tiankang Chuangji Pharmaceutical Technology Co., Ltd.[14] Financial Instruments - The company redeemed structured deposits from Xiamen International Bank, receiving a principal of 10 million RMB and interest of 71,600 RMB[15] - The company redeemed structured deposits of 15 million RMB from Xiamen International Bank, receiving interest of 105,000 RMB[15] Earnings Per Share - The company’s basic earnings per share decreased by 39.13% to ¥0.14, compared to ¥0.23 in Q1 2023[4] - The basic and diluted earnings per share for Q1 2024 are both CNY 0.14, compared to CNY 0.23 in Q1 2023, representing a decrease of 39.1%[21] Audit Status - The company has not undergone an audit for the Q1 2024 report[24]